Restrictive insurance policies, such as step therapy and prior authorization, which add hurdles for patients
Offer: modified-release metformin, and an SGLT-2 inhibitor If metformin is contraindicated or not tolerated, offer monotherapy with an SGLT-2 inhibitor
Cardiovascular side effects with semaglutide are generally mild, and the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in people with established heart disease
But with that power comes risk
Description BPC-157 Peptide The BPC-157 peptide, also known as Pentadecapeptide BPC 157 or Body Protection Compound 157, is a synthetic compound that has been suggested in various studies to assist with healing joint, tendon, and muscle tissue, as well as nerve tissue